Treatment of systemic sclerosis-related interstitial lung disease: A review of existing and emerging therapies

Annals of the American Thoracic Society

Volumn 13, Issue 11, 2016, Pages 2045-2056

  Volkmann, Elizabeth R ^a   Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pulmonary fibrosis; Scleroderma; Therapeutics

Indexed keywords

ABATACEPT; ABITUZUMAB; ANTIFIBROTIC AGENT; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; CYCLOPHOSPHAMIDE; DABIGATRAN; ENDOTHELIN 1 DERIVATIVE; INTERLEUKIN 6; MYCOPHENOLIC ACID; NILOTINIB; NINTEDANIB; POMALIDOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; TADALAFIL; IMMUNOSUPPRESSIVE AGENT;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; PATHOGENESIS; REVIEW; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; COMPLICATION; LUNG; LUNG FIBROSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; MYCOPHENOLIC ACID; PULMONARY FIBROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84995475493     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201606-426FR     Document Type: Review

References (114)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017-1026.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69: 1809-1815.
3. Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, Delannoy V, Queyrel V, Duhamel A, Matran R, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006;33: 1789-1801.
4. De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistelli R, Danza FM, Zoli A, Ferraccioli G. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005;6:96.
5. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-1586.
6. Reveille JD, Solomon DH; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidencebased guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003;49: 399-412.
7. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
8. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289.
9. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-2255.
10. Wells AU. Pulmonary function tests in connective tissue disease [review]. Semin Respir Crit Care Med 2007;28:379-388.
11. Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, Colby TV, Denton CP, Black CM, du Bois RM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004;232:560-567.
12. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007;56:2005-2012.
13. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, et al.; Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008;177:91-98.
14. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43: 2437-2444.
15. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-150.
16. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
17. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, Wells AU, Denton CP. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014;66:1625-1635.
18. Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-1254.
19. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Gabbay E, et al. Extent of disease on highresolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013;52:155-160.
20. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011;63:3078-3085.
21. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin RM, Draeger H, Nair DK, Fritzler MJ, Reveille JD, Arnett FC, et al.; GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
22. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40:435-446.
23. Liu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, Reveille JD, Assassi S. Does C-reactive protein predict the longterm progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013; 65:1375-1380.
24. Wu M, Pedroza C, Salazar G, Zhou X, Reveille J, Mayes MD, Assassi S. Plasma MCP-1 and IL-10 levels predict long-term progression of interstitial lung disease in patients with early systemic sclerosis [abstract]. Arthritis Rheum 2013;65:S742.
25. Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Tolédano C, Cabane J, Dinh-Xuan AT. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011;38: 1355-1360.
26. Schupp J, Becker M, Günther J, Müller-Quernheim J, Riemekasten G, Prasse A. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J 2014;43: 1530-1532.
27. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014;370:433-443.
28. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004;31:1112-1120.
29. Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, Speich R, Frauenfelder T, Distler O. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256-3261.
30. Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep 2014;16:411.
31. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42-54.
32. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM; Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009;36:773-780.
33. Fanti S, De Fabritiis A, Aloisi D, Dondi M, Marengo M, Compagnone G, Fallani F, Cavalli A, Monetti N. Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med 1994;35:1933-1936.
34. Willis BC, Borok Z. TGF-b-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525-L534.
35. Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol 2010;22: 683-689.
36. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-1485.
37. Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C. Presence of CD41CD81 double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007;56:3459-3467.
38. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B. Production of Type 2 cytokines by CD81 lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42:1168-1178.
39. Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011;13:R166.
40. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Komura K, Sato S. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240-242.
41. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML. A TGFb-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694-705.
42. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998;41: 2039-2047.
43. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011; 10:276-281.
44. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013; 15:215.
45. Jain S, Shahane A, Derk CT. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Inflamm Allergy Drug Targets 2012;11:266-277.
46. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis- associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009;11:111-119.
47. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, et al. Highdose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-1203.
48. Furst DE, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG, Paulus HE. Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32:584-593.
49. Lynch JP III, Saggar R, Weigt SS, Zisman DA, White ES. Usual interstitial pneumonia. Semin Respir Crit Care Med 2006;27: 634-651.
50. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-3970.
51. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666.
52. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-844.
53. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-954.
54. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, et al. Treatment of sclerodermainterstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest 2009;136:1333-1340.
55. Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011;21:2455-2465.
56. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, et al.; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-1034.
57. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology (Oxford) 2007;46:442-445.
58. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009;48:1595-1599.
59. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008;133:455-460.
60. Simeón-Aznar CP, Fonollosa-PláV, Tolosa-Vilella C, Selva- O'Callaghan A, Solans-LaquéR, Vilardell-Tarrés M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011;30:1393-1398.
61. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130: 30-36.
62. ZamoraAC, WoltersPJ, CollardHR, ConnollyMK, Elicker BM, WebbWR, King TE Jr, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150-155.
63. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, et al.; Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial. Lancet Respir Med 2016;4:708-719.
64. Saketkoo LA, Lammi MR, Fischer A, Molitor J, Steen VD; PHAROS Investigators. Mycophenolate mofetil (MMF) use in scleroderma patients with pulmonary hypertension: FVC, outcomes, and survival: observations from the Pulmonary Hypertension Recognition and Outcomes in Scleroderma (Pharos) cohort [abstract]. Ann Rheum Dis 2015;74(Suppl 2):820.
65. Zheng Y, Li M, Zhang Y, Shi X, Li L, Jin M. The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatol Int 2010;30:341-348.
66. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-630.
67. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-3168.
68. De Santis M, Bosello SL, Peluso G, Pinnelli M, Alivernini S, Zizzo G, Bocci M, Capacci A, La Torre G, Mannocci A, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 2012;6:9-17.
69. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;30(2, Suppl 71):S17-S22.
70. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015;44:428-436.
71. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S. Successful treatment of resistant sclerodermaassociated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008;47:552-553.
72. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49: 271-280.
73. Leask A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal 2011;5:125-129.
74. Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179: 163-174.
75. Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology (Oxford) 2010;49:2147-2153.
76. Furuya Y, Kuwana M. Effect of bosentan on systemic sclerosis- associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 2011;38: 2186-2192.
77. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-2108.
78. Muangchant C, Pope JE. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 2013;31(2, Suppl 76): 122-134.
79. Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012;71: 1235-1242.
80. Khanna D, Denton CP, Jahreis A, van Laar JM, Cheng S, Spotswood H, Pope JE, Allanore Y, Muller-Ladner U, Siegel J, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: weekdata from the faSScinate trial [abstract presented at meeting of the European League against Rheumatism (EULAR), Rome, Italy, June 10-13, 2015]. Ann Rheum Dis 2015;74 (Suppl 2):87-88.
81. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-b and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316.
82. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011;63:3540-3546.
83. Gordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang WT, Lyman S, Crow MK, et al. Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol 2014;32(6, Suppl 86): S-189-S-193.
84. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-1009.
85. Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012;167:1138-1144.
86. Distler O, Distler JHW, Varga J, Denton CP, Lafyatis RA, Wigley FM, Schett GA. Multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]. Arthritis Rheum 2010;62(Suppl 10):560.
87. Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, et al.; Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 2014;16:R144.
88. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68: 4774-4782.
89. McCormack PL. Nintedanib: first global approval. Drugs 2015;75: 129-139.
90. Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016;75:883-890.
91. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
92. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-408.
93. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999;276:L311-L318.
94. Yuko O, Kawaguchi Y, Takagi K, Ichida H, Katsumata Y, Gono T, Okamoto Y. Pirfenidone and BIBF1120 suppress collagen synthesis in skin fibroblast from patients with systemic sclerosis [abstract]. Arthritis Rheum 2013;65:652.
95. Miura Y, Saito T, Fujita K, Tsunoda Y, Tanaka T, Takoi H, Yatagai Y, Rin S, Sekine A, Hayashihara K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:235-238.
96. Khanna D, Albera C, Fischer A, Seibold JR, Raghu G, Khalidi N, Chung L, Schipou E, Chen D, Gorina E. Safety and tolerability of pirfenidone in patients with systemic sclerosis-associated interstitial lung disease: the LOTUSS study [abstract]. Ann Rheum Dis 2015;74:816.
97. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford) 2015;54:2126-2133.
98. van Laar JM, Sullivan K. Stem cell transplantation in systemic sclerosis. Curr Opin Rheumatol 2013;25:719-725.
99. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, et al.; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-2498.
100. Bernstein EJ, Peterson ER, Sell JL, D'Ovidio F, Arcasoy SM, Bathon JM, Lederer DJ. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol 2015;67:1314-1322.
101. Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, Kron A, Johnson SR. Survival after lung transplantation in systemic sclerosis: a systematic review. Respir Med 2013;107:2081-2087.
102. Sottile PD, Iturbe D, Katsumoto TR, Connolly MK, Collard HR, Leard LA, Hays S, Golden JA, Hoopes C, Kukreja J, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation 2013;95:975-980.
103. Crespo MM, Bermudez CA, Dew MA, Johnson BA, George MP, Bhama J, Morrell M, D'Cunha J, Shigemura N, Richards TJ, et al. Lung transplantation in patients with scleroderma compared with pulmonary fibrosis: short and long-term outcomes in a single institution. Ann Am Thorac Soc 2016;13:784-792.
104. Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, Weigt S, Charan D, Abtin F, Johannes J, et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction: a comprehensive single center experience. Ann Am Thorac Soc 2016; 13:793-802.
105. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease- Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung disease. J Rheumatol 2014;41: 792-798.
106. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.; ATS/ ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
107. Volkmann ER, Tashkin DP, Li N, Furst DE, Clements PJ, Elashoff RM. Development of a composite outcome measure for systemic sclerosis related interstitial lung disease. Rheumatology (Sunnyvale) 2015;5:154.
108. Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med 2014;43:e329-e343.
109. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, Seibold JR, Silver RM, Tashkin DP, Wells AU. Systemic sclerosis- associated interstitial lung disease: proposed recommendations for future randomized clinical trials [review]. Clin Exp Rheumatol 2010; 28(2, Suppl 58):S55-S62.
110. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 1994;37:1290-1296.
111. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, et al.; Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011;63:2797-2808.
112. Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev 2013;22:236-243.
113. BéreznéA, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008;35:1064-1072.
114. Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum 2015;44: 437-444.